Metabolomic Study To Identify Common Metabolites In Two Different Mouse Models Of Hypertension

Metabolomic Study to Identify Common Metabolites in Two Different Mouse Models of Hypertension Recent studies have reflected the importance of the body’s microbiome and associated metabolites and their changes in hypertension. In the current study, we hypothesized that metabolite changes common between hypertension models may unify hypertension’s pathophysiology with respect to metabolites. Two different mice models of experimental hypertension were used in the study: (1) L-arginine methyl ester hydrochloride (L-NAME)/High salt diet induced hypertension (LSHTN) and (2) angiotensin II induced hypertension (AHTN). Untargeted global metabolomics analysis in serum and urine samples were performed to identify common metabolites altered across both hypertensive models, and the resulting data were analyzed using MetaboAnalyst software and compared to control mice. A list of metabolites that were altered significantly in both models of hypertension were identified. A total of 41 serum metabolites were identified as being altered significantly in any hypertensive model compared to controls. Of these, however, only 4 were increased significantly, and 10 were decreased significantly in common across both hypertensive groups. In the urine, 6 metabolites were altered significantly in any hypertensive group with respect to control, however, 0 of them were common between the hypertensive groups. These findings demonstrate that a modest, but potentially important, number of serum metabolites are commonly altered between experimental hypertension models. Further studies to understand the role of these identified metabolites may lead to a greater understanding of the association between gut dysbiosis and hypertension. Submitted to American Heart Association Council on Hypertension Scientific Sessions (September 27-29, 2021, Virtual)Abstract#: 21-HBPR-A-578-AHA